What is the design of the ongoing Phase III ELRISE trial of elritercept in lower-risk MDS?
Elritercept versus luspatercept in transfusion-dependent patients with ring sideroblast-positive MDS
Elritercept versus erythropoiesis-stimulating agents (ESAs) in transfusion-dependent patients
Elritercept versus placebo in ESA-refractory patients with ring sideroblast-positive MDS only